afm11
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2014 (NCT02106091)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
CD3E activator
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- afm11
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02848911 | Phase 1 | Oct 1, 2016 | Affimed GmbH |
| NCT02106091 | Phase 1 | Apr 1, 2014 | Affimed GmbH |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Affimed GmbH | For profit | 2 | 2 | 1 | 2014 |
1 organizations
Page 1 / 1